摘要
目的:探讨多种肿瘤标志物联合检测在食管癌转移及预后判断中的应用价值。方法:选择有转移的食管癌患者(转移组)53例,无转移的食管癌患者(未转移组)91例,采用多种肿瘤标志物蛋白芯片技术对两组患者的血清进行检测。12种肿瘤标志物为CA19-9、NSE、CEA、CA242、Fer、β-HCG及AFP、f-PSA、PSA、CA125、HCG及CA15-3,并对其预后进行随访。结果:转移组的阳性率为60.4%(32/53),显著高于未转移组6.6%(6/91)(P<0.01);2年随访发现:肿瘤标志物阳性患者死亡率为60.0%(21/35),显著高于阴性组23.8%(24/101)。结论:多种肿瘤标志物联合检测可以为食管癌的转移提供诊断线索,并且对预后评估具有一定的指导意义。
Objective:To evaluate the effect of multi-tumor markers in diagnosis of aversion and prognosis in esophageal carcinoma. Methods :Two groups of esophageal carcinoma patients, in which 53 patients had lymph nodes or/and organs infiltration and 91 patients had no infiltration. The serum levels of 12 tumor markers were measured by using the protein-chip system in the two groups of patients. The common tumor markers in the serum include CA19-9, NSE, CEA, CA242, Fer, β-HCG, AFP, f-PSA, PSA, CA125, HCG and CA15-3. We have made a follow-up to the patients. Results:The positive ratio of the infiltration patients was 60. 4% (32/ 53), the positive ratio of no infiltration patients was 6.6% (6/91), there was significant difference between them(P 〈0. 01 ); The mortality rate of tumor marker positive patients was 60. 0% (21/35) in two years, and that of negative patients was 23.8% (24/101). Conclusion :The application of protein-chip system for tumor markers may pay an important role in diagnosis of aversion and prognosis in esophageal carcinoma.
出处
《临床肿瘤学杂志》
CAS
2007年第7期512-513,516,共3页
Chinese Clinical Oncology
关键词
肿瘤标志物
蛋白芯片
食管癌
转移
预后
Tumor marker
Protein-chip
Esophageal carcinoma
Aversion
Prognosis